Despite missing primary endpoints, the endocannabinoid modulator demonstrated encouraging pain score improvements in subgroup ...
The timed run also reduced total review time from almost 26 hours for Enveda’s four reviewers to just under three hours, ...
Investigational oral therapy targeting rhodopsin protein misfolding is currently undergoing Phase 1/2 clinical evaluation for ...
Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76 ...
Accord now holds two pegfilgrastim biosimilars in one market, its in-house Ennumo and the acquired Udenyca. Owning both the ...
TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours ...
MEPSGEN US, Inc., a global innovator in drug delivery system platforms, announced the launch of NanoCalibur® Mini, an ...
NMPA accepts new indication application following Phase II MIZAR-003 results demonstrating a 57% reduction in the risk of ...
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple ...
For any company with a Japan P&L, that decision collapses into eight numbers. Each is set out below in the same four lines: ...
Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis ...
Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. announced a research agreement to evaluate the use of Lunit SCOPE IO, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results